51,703 results match your criteria Crohn's Disease and NOD2 CARD15


Assessment of Bowel Inflammation and Strictures by Magnetic Resonance Enterography in Long-term Crohn´s Disease.

J Crohns Colitis 2018 Dec 12. Epub 2018 Dec 12.

Department of Radiology, Akershus University Hospital, Lørenskog, Norway.

Background: Crohns disease (CD) is a chronic inflammation in the gut that often progresses to fibrosis. Magnetic Resonance Enterography (MRE) is an important diagnostic tool in evaluating CD. We aimed to assess the prevalence of inflammation and stricturing disease in patients with long-term CD and investigate associations with clinical factors. Read More

View Article
December 2018

Management of paediatric patients with medically-refractory Crohn's disease using Ustekinumab: A multi-centred cohort study.

J Crohns Colitis 2018 Dec 12. Epub 2018 Dec 12.

Division of Gastroenterology, Montreal Children's Hospital, Department of Paediatrics, McGill University, Montreal, Quebec, Canada.

Background: Ustekinumab (UST) is effective in the treatment of adults with moderate to severe Crohn's disease (CD). There is a paucity of data on its use in children.

Aim: To evaluate the response to UST in children with moderate to severe CD. Read More

View Article
December 2018
1 Read

Mucosal healing and bacterial composition in response to enteral nutrition versus steroid based induction therapy - a randomized prospective clinical trial in children with Crohn's disease.

J Crohns Colitis 2018 Dec 12. Epub 2018 Dec 12.

Hôpital Necker Enfants Malades Université Sorbonne Paris Cité, Paris, APHP.

Exclusive Enteral Nutrition (EEN) is as efficacious as corticosteroids (CS) to induce remission in Crohn's disease (CD), without their adverse effects. EEN seems to be more efficient than steroids to induce mucosal healing, but the underlying molecular mechanisms are only sparsely understood. We aimed in the present work to study the anti-inflammatory effects of EEN with Modulen IBD® versus CS in active pediatric CD and to assess its modulatory effects on the intestinal microbiota as compared to steroids. Read More

View Article
December 2018

Gastric Focal Neutrophil Infiltration and Wide Duodenal Gastric Foveolar Metaplasia Are Histologic Discriminative Markers for Crohn's Disease and Behçet's Disease.

Digestion 2018 Dec 12:1-10. Epub 2018 Dec 12.

Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.

Background/aims: Behçet's disease (BD) with intestinal lesions and Crohn's disease (CD) share clinical features. However, no report has compared the 2 diseases with regard to lesions of the upper gastrointestinal tract (UGT). We aimed to evaluate endoscopic and histologic findings of UGT in CD and BD. Read More

View Article
December 2018

Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

J Pediatr Gastroenterol Nutr 2018 Dec 11. Epub 2018 Dec 11.

Section of Pediatric Gastroenterology and Nutrition, Texas Children's Hospital, Baylor College of Medicine, Children's Nutrition and Research Center, Houston, TX.

Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. Read More

View Article
December 2018

Role of Vacuum-Assisted Closure in the Management of Crohn Anal Fistulas.

Adv Skin Wound Care 2018 Dec 12. Epub 2018 Dec 12.

At the Poznań University of Medical Sciences in Poznań, Poland, Jacek Hermann, PhD, is Chair, Department of General and Endocrine Surgery and Gastroenterologic Oncology; Tomasz Banasiewicz is Chair, Department of General and Endocrine Surgery and Gastroenterologic Oncology; and Barbara Kołodziejczak, PhD, is Chair, Department of Computer Science and Statistics. The authors have disclosed no financial relationships related to this article. Submitted January 28, 2018; accepted in revised form May 25, 2018.

Background: Patients with Crohn disease-related anal fistulas are treated with debridement of fistulous tracts and the placement of noncutting setons (NCSs). However, to reduce the high recurrence rate, there is still a need to develop more effective treatment methods.

Objective: To compare NCS with vacuum-assisted closure (VAC) treatment. Read More

View Article
December 2018
1 Read

Comparison of MRI Activity Scoring Systems and Features for the Terminal Ileum in Patients With Crohn Disease.

AJR Am J Roentgenol 2018 Dec 12:W1-W7. Epub 2018 Dec 12.

1 Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.

Objective: The purpose of this study was to evaluate four previously validated MRI activity scoring systems for diagnosis and grading of Crohn disease (CD) in the terminal ileum against an endoscopic and histopathologic reference standard.

Subjects And Methods: Ethics approval and written informed consent were obtained. Subjects with known or suspected CD were prospectively recruited between December 2011 and August 2014. Read More

View Article
December 2018

THE ONSET OF CLINICAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS.

Arq Gastroenterol 2018 Jul-Sep;55(3):290-295

Universidade do Estado da Bahia, Departamento de Ciências da Vida, Salvador, BA, Brasil.

Background: The diagnosis of inflammatory bowel disease is often delayed because of the lack of an ability to recognize its major clinical manifestations.

Objective: Our study aimed to describe the onset of clinical manifestations in inflammatory bowel disease patients.

Methods: A cross-sectional study. Read More

View Article
October 2017

ANALYSIS OF RISK FACTORS AND POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH CROHN'S DISEASE.

Arq Gastroenterol 2018 Jul-Sep;55(3):252-257

Universidade Estadual Paulista (UNESP), Faculdade de Medicina, Departamento de Cirurgia e Ortopedia, Botucatu, SP, Brasil.

Background: The post-operative complications rate is greater in patients with Crohn's disease than in other abdominal surgeries due to other benign conditions. Prevention and management of such complications are important factors in the care of these patients.

Objective: The objectives of this research are to analyze the rate of postoperative complications and the major risk factors in patients with Crohn's disease. Read More

View Article
February 2018

VITAMIN D DEFICIENCY AMONG INFLAMMATORYBOWEL DISEASE PATIENTS IN ARGENTINA: A CROSS-SECTIONAL STUDY.

Arq Gastroenterol 2018 Jul-Sep;55(3):216-220

Gastroenterology Department, Hospital Británico de Buenos Aires, Buenos Aires, Argentina.

Background: An association has been established between low serum values of vitamin D and inflammatory bowel disease. There is a lack of evidence on whether this association is still observed in regions where sun exposure throughout the year is higher.

Objective: To compare the prevalence of vitamin D deficiency between inflammatory bowel disease patients and healthy controls. Read More

View Article
January 2018

INFLAMMATORY BOWEL DISEASE: IMPACT ON SCORES OF QUALITY OF LIFE, DEPRESSION AND ANXIETY IN PATIENTS ATTENDING A TERTIARY CARE CENTER IN BRAZIL.

Arq Gastroenterol 2018 Jul-Sep;55(3):202-207

Programa de Pós-Graduação: Ciências da Gastroenterologia e Hepatologia, Hospital de Clínicas de Porto Alegre, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil.

Background: Inflammatory bowel disease frequently affects patients at working age, compromising their quality of life in several levels: physical, psychological, familial and social. Few studies have evaluated the impact of Inflammatory bowel disease on quality of life, anxiety and depression in Brazilian patients.

Objective: Evaluate quality of life and its correlation with psychological aspects of patients with inflammatory bowel disease through the Inflammatory Bowel Disease Questionnaire and Hospital Anxiety and Depression Scale. Read More

View Article
November 2017

Inflammatory arthritis: a unique presentation of human anaplasmosis.

Clin Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Rheumatology Department at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Hempstead, NY, USA.

Human granulocytic anaplasmosis (HGA) is a tickborne rickettsial disease caused by the bacterium Anaplasma phagocytophilum. Reported cases have increased with the highest incidence in the Northeast. To our knowledge, this is the first report of anaplasmosis associated with an inflammatory arthritis. Read More

View Article
December 2018

Successful medical treatment for a Crohn's disease patient with a perforation by a second-generation patency capsule.

Endosc Int Open 2018 Dec 10;6(12):E1436-E1438. Epub 2018 Dec 10.

Division of Gastroenterology and Hematology/Oncology Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.

 Symptomatic capsule retention is a very rare adverse event following patency capsule, and the vast majority of cases are resolved without either surgical or endoscopic intervention. We herein describe a rare case of small bowel perforation after swallowing a patency capsule in a 37-year-old man suspected of having Crohn's disease. Read More

View Article
December 2018

Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics.

BMJ Open Gastroenterol 2018 9;5(1):e000243. Epub 2018 Nov 9.

Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California, USA.

Uncertainty exists regarding safety and efficacy of dual biological therapy (DBT) in inflammatory bowel disease. We present four cases of DBT in Crohn's disease. Three patients had refractory disease non-responsive to biological monotherapy or combination therapy with immunomodulators. Read More

View Article
November 2018

School-related experience and performance with inflammatory bowel disease: results from a cross-sectional survey in 675 children and their parents.

BMJ Open Gastroenterol 2018 24;5(1):e000236. Epub 2018 Nov 24.

Division of Epidemiology and Biometry, Medical Faculty, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.

Objective: We describe school performance and experience in children with inflammatory bowel disease (IBD) across Germany and Austria. Predictors of compromised performance and satisfaction were evaluated to identify subgroups of increased risk.

Design: This cross-sectional analysis was based on a postal survey in children aged 10-15 with Crohn's disease, ulcerative colitis or unclassified IBD and their families. Read More

View Article
November 2018

Soluble transferrin receptor and soluble transferrin receptor/log ferritin index in diagnosis of iron deficiency anemia in pediatric inflammatory bowel disease.

Dig Liver Dis 2018 Nov 22. Epub 2018 Nov 22.

Department of Pediatrics and Gastroenterology, Medical University of Lublin, Lublin, Poland.

Background: There is no single reliable marker of iron homeostasis in inflammatory bowel disease.

Aims: To determine diagnostic usefulness of soluble transferrin receptor and soluble transferrin receptor/log ferritin index in iron deficiency anemia in children with inflammatory bowel disease.

Methods: We assessed soluble transferrin receptor in serum and calculated soluble transferrin receptor/log ferritin index in 75 children with inflammatory bowel disease. Read More

View Article
November 2018

Immunotherapeutic Effects of β-D Mannuronic Acid on IL-4, GATA3, IL-17 and RORC Gene Expression in the PBMC of Patients with Inflammatory Bowel Diseases.

Iran J Allergy Asthma Immunol 2018 Aug 12;17(4):308-317. Epub 2018 Aug 12.

Department of Immunology, School of Public Health, International Campus, Tehran University of Medical Sciences, Tehran, Iran.

Inflammatory bowel diseases (IBD) are chronic relapsing immune-mediated disorders that result from an aberrant immunological response. IBD comprises of Crohn's disease (CD) and ulcerative colitis (UC). The precise aetiology of IBD has not been fully understood, however, recent studies support the hypothesis that patients with IBD have a dysregulated immune response to endogenous bacteria in the gastrointestinal tract (GIT). Read More

View Article
August 2018
1.013 Impact Factor

Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis.

Dig Dis Sci 2018 Dec 7. Epub 2018 Dec 7.

The Royal Liverpool and Broad Green University Hospitals NHS Foundation Trust, Liverpool, UK.

Background: Pharmacokinetic data suggest that standard induction dosing schedules may not be sufficient in patients with acute severe colitis (ASUC). Hence, intensified induction regimes are increasingly used in the rescue treatment of hospitalized patients with ASUC to avoid the need for colectomy although the evidence for this is uncertain.

Aim: To conduct a systematic review of short- and long-term efficacy outcomes from accelerated infliximab induction studies. Read More

View Article
December 2018

Raising the Barr: An Unexpected Lesion at Ileal-Cecal Resection.

Dig Dis Sci 2018 Dec 7. Epub 2018 Dec 7.

Crohn's and Colitis Center, Brigham and Women's Hospital, Boston, MA, USA.

View Article
December 2018

Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes.

Dig Dis Sci 2018 Dec 7. Epub 2018 Dec 7.

The Edinburgh IBD Unit, Western General Hospital, Edinburgh, EH4 2XU, UK.

Background: Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn's disease.

Aim: The aim of this work was to prospectively evaluate clinical outcomes in a cohort of patients with Crohn's disease switching from Remicade to CT-P13.

Methods: A prospective service evaluation was performed. Read More

View Article
December 2018

Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis.

Int J Colorectal Dis 2018 Dec 10. Epub 2018 Dec 10.

Department of Colorectal Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, 44195, USA.

Aim: The association between preoperative use of monoclonal antibodies in inflammatory bowel disease (IBD) patients and postoperative complications is controversial, especially for the latest approved biologics, ustekinumab and vedolizumab, where data is limited. We hypothesized that ustekinumab-treated patients would have a similar overall postoperative complication rate as vedolizumab-treated patients. The aim of this study was to compare postoperative complications in patients receiving preoperative ustekinumab vs. Read More

View Article
December 2018

Biosimilars for Management of Crohn Disease.

Ann Intern Med 2018 Dec 11. Epub 2018 Dec 11.

Odense University Hospital, Odense, Denmark (M.A.A.).

View Article
December 2018

Local Stem Cell Therapy for Crohn's Perianal Fistulae.

Inflamm Bowel Dis 2018 Dec 11. Epub 2018 Dec 11.

Center for Inflammatory Bowel Disease, Digestive Disease and Surgical Institute, Cleveland Clinic, Cleveland, Ohio, USA.

View Article
December 2018

Acupuncture in Inflammatory Bowel Disease.

Inflamm Bowel Dis 2018 Dec 11. Epub 2018 Dec 11.

Department of Gastroenterology, Hepatology & Nutrition, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio.

Scientific research into the effects and mechanisms of acupuncture for gastrointestinal diseases including inflammatory bowel disease has been rapidly growing in the past several decades. In this review, we discuss the history, theory, and methodology of acupuncture and review potentially beneficial mechanisms of action of acupuncture for managing inflammatory bowel disease. Acupuncture has been shown to decrease disease activity and inflammation via increase of vagal activity in inflammatory bowel disease. Read More

View Article
December 2018

Refractory pyoderma gangrenosum in a patient with Crohn´s Disease: complete response to Ustekinumab.

J Crohns Colitis 2018 Dec 7. Epub 2018 Dec 7.

Gastroenterology department, Hospital Garcia de Orta, Almada, Portugal.

View Article
December 2018

Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease.

Inflamm Bowel Dis 2018 Dec 9. Epub 2018 Dec 9.

Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Background: Corticosteroids (CS) and anti-TNF drugs are used to treat Crohn's disease (CD). In this study, we assessed the net health benefit of initiating anti-TNF therapy relative to additional CS use in CD using a novel combination of a retrospective cohort study and a simulation model.

Methods: Using Medicaid data from 2001 to 2005 and Medicare data from 2006 to 2013, beneficiaries were identified with CD and CS use who subsequently received either an anti-TNF or reached a cumulative dose of >3000 mg CS during the year. Read More

View Article
December 2018

Starch Consumption May Modify Antiglycan Antibodies and Fecal Fungal Composition in Patients With Ileo-Anal Pouch.

Inflamm Bowel Dis 2018 Dec 11. Epub 2018 Dec 11.

Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.

Background: Inflammatory bowel diseases (IBDs) are characterized by serologic responses to glycans. Patients with ulcerative colitis (UC) after proctocolectomy with ileo-anal anastomosis (pouch surgery) may develop inflammation (pouchitis) that resembles Crohn's disease (CD). We hypothesized that patients' serologic responses were affected by their consumption of dietary sugars. Read More

View Article
December 2018

The role of intravenous Contrast Agent in the Sonographic Assessment of Crohn's Disease Activity: Is Contrast Agent Injection Necessary?

J Crohns Colitis 2018 Dec 8. Epub 2018 Dec 8.

Department of Radiology, Valencia (SPAIN).

Background: the literature shows that contrast-enhanced ultrasound (CEUS) is superior to wall thickness or color Doppler imaging (CDI) in predicting disease activity using endoscopy as the reference standard.

Objective: to determine in patients with Crohn´s disease (CD) whether the evaluation of wall thickness or CDI before CEUS examination could help decide when the injection of contrast agent is justified as a means for detecting disease activity as determined at endoscopy, without reducing the accuracy of ultrasound.

Material & Methods: 180 patients with CD underwent both colonoscopy and US, including mural thickness, CDI and CEUS evaluation, prospectively as part of clinical care. Read More

View Article
December 2018

Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study.

Ann Intern Med 2018 Dec 11. Epub 2018 Dec 11.

Caisse Nationale de l'Assurance Maladie, Paris, and Hôpital Bicêtre, Le Kremlin-Bicêtre, France (A.M., J.C.).

Background: CT-P13 is a biosimilar of the reference product (RP) infliximab, with demonstrated efficacy and safety for some inflammatory arthritides. It was approved for the treatment of Crohn disease (CD) on that basis, without specific studies examining its effects in CD.

Objective: To compare the effectiveness and safety of CT-P13 and RP in infliximab-naive patients with CD. Read More

View Article
December 2018

[Fecal microbiota transplantation through colonoscopy for Clostridium difficile recurrent infection. Report of eight cases].

Rev Med Chil 2018 Aug;146(8):823-830

Departamento de Medicina Interna, Clínica Las Condes, Santiago, Chile.

Background: Most cases of Clostridium difficile infection (CDI) respond to a standard course of antibiotics, however recurrent CDI is becoming common and alternative therapeutic strategies are needed. In this scenario, fecal microbiota transplantation (FMT) has been suggested.

Aim: To describe the efficacy and safety of FMT for the treatment of recurrent CDI. Read More

View Article

Development of multiplex PCR and multi-color fluorescent in situ hybridization (-FISH) coupled protocol for detection and imaging of multi-pathogens involved in inflammatory bowel disease.

Gut Pathog 2018 5;10:51. Epub 2018 Dec 5.

Division of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, 4110 Libra Drive, Orlando, FL USA.

Background: Several pathogens have been debated to play a role in inflammatory bowel disease (IBD) including Crohn's disease (CD). None of these pathogens have been investigated together in same clinical samples. We developed a multiplex PCR and multi-color fluorescent in situ hybridization (-FISH) protocols for simultaneous detection of CD-associated pathogens including subspecies (MAP), , and adherent-invasive strain LF82. Read More

View Article
December 2018

Laparoscopy Combined with Enhanced Recovery Pathway in Ileocecal Resection for Crohn's Disease: A Randomized Study.

Gastroenterol Res Pract 2018 11;2018:9648674. Epub 2018 Nov 11.

Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Background And Aims: Laparoscopic approach is recommended as the first-choice option for simple ileocecal resections. However, there are no randomized trials that have focused on patients with Crohn's disease (CD) treated by laparoscopy and enhanced recovery pathway. The aim of the present study is to prospectively evaluate the feasibility, safety, and short-term outcomes of laparoscopy with enhanced recovery pathway for CD patients undergoing ileocecal resection. Read More

View Article
November 2018

Severe neutropenia in a breastfed infant: a case report and discussion of the differential diagnosis.

Int Med Case Rep J 2018 15;11:333-337. Epub 2018 Nov 15.

Department of Pediatrics, Queen Paola Children's Hospital, Antwerp, Belgium,

Neonatal neutropenia is regularly seen with variable etiology. We describe a breastfed infant with maternal medication use as a probable cause of neonatal neutropenia. An 8 days old exclusively breastfed female infant of Arab-Berber descent was referred to our hospital because of an infection of the umbilicus. Read More

View Article
November 2018

Cell-based therapy for Crohn's disease: time to consider optimization.

Authors:
Amy L Lightner

Nat Rev Gastroenterol Hepatol 2018 Dec 7. Epub 2018 Dec 7.

Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA.

View Article
December 2018

Gut microbiome structure and metabolic activity in inflammatory bowel disease.

Nat Microbiol 2018 Dec 10. Epub 2018 Dec 10.

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

The inflammatory bowel diseases (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome-the molecular interface between host and microbiota-are less well understood. To address this gap, we performed untargeted metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery (n = 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients. Read More

View Article
December 2018

First report of coexistence of MOG-antibody-positive disease and Crohn's disease.

Mult Scler Relat Disord 2018 Dec 3;28:1-3. Epub 2018 Dec 3.

Department of Neurology, CHU UCL Namur site Godinne, Université catholique de Louvain (UCLouvain), Avenue G. Thérasse 1, 5530 Yvoir, Belgium. Electronic address:

View Article
December 2018

No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases.

Gastroenterology 2018 Dec 6. Epub 2018 Dec 6.

Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:

Background & Aims: Patients with inflammatory bowel diseases (IBD) who have post-inflammatory polyps (PIPs) have an increased risk of colorectal neoplasia (CRN). European guidelines propose that patients with PIPs receive more frequent surveillance colonoscopies, despite limited evidence of this increased risk. We aimed to define the risk of CRN and colectomy in patients with IBD and PIPs. Read More

View Article
December 2018

Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency.

Cytotherapy 2018 Dec 6. Epub 2018 Dec 6.

The Arthritis Program, University Health Network, Toronto, Canada;; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada; Cell Therapy Program, University Health Network, Toronto, Canada; Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada. Electronic address:

Mesenchymal stromal cell (MSC) therapies have been pursued for a broad spectrum of indications but mixed reports on clinical efficacy have given rise to some degree of skepticism regarding the effectiveness of this approach. However, recent reports of successful clinical outcomes and regulatory approvals for graft-versus-host disease, Crohn's disease and critical limb ischemia have prompted a shift in this perspective. With hundreds of clinical trials involving MSCs currently underway and an increasing demand for large-scale manufacturing protocols, there is a critical need to develop standards that can be applied to processing methods and to establish consensus assays for both MSC processing control and MSC product release. Read More

View Article
December 2018

Adherent/invasive Escherichia coli (AIEC) isolates from asymptomatic people: new E. coli ST131 O25:H4/H30-Rx virotypes.

Ann Clin Microbiol Antimicrob 2018 Dec 10;17(1):42. Epub 2018 Dec 10.

Benemérita Universidad Autónoma de Puebla, Posgrado en Ciencias Microbiológicas, Centro de Investigaciones en Ciencias Microbiológicas, Instituto de Ciencias, Puebla, Mexico.

Background: The widespread Escherichia coli clone ST131 implicated in multidrug-resistant infections has been recently reported, the majority belonging to O25:H4 serotype and classified into five main virotypes in accordance with the virulence genes carried.

Methods: Pathogenicity Islands I and II (PAI-I and PAI-II) were determined using conventional PCR protocols from a set of four E. coli CTX ST131 O25:H4/H30-Rx strains collected from healthy donors' stool. Read More

View Article
December 2018

Leucine Rich Repeat Proteins: Sequences, Mutations, Structures, and Diseases.

Protein Pept Lett 2018 Dec 8. Epub 2018 Dec 8.

University of Virginia - Department of Biology Charlottesville, Virginia. United States.

Mutations in the genes encoding Leucine Rich Repeat (LRR) containing proteins are associated with over sixty human diseases; these include high myopia, mitochondrial encephalomyopathy, and Crohn's disease. These mutations occur frequently within the LRR domains and within the regions that shield the hydrophobic core of the LRR domain. The amino acid sequences of fifty-five LRR proteins have been published. Read More

View Article
December 2018

[Gastrointestinal manifestations in immunodeficiencies with monogenic origin].

Orv Hetil 2018 Dec;159(49):2050-2056

Gyermekgyógyászati Klinika, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.

Although very early onset inflammatory bowel disease that develops in early childhood (before the age of 6 years) has a different etiology from Crohn's disease and ulcerative colitis, it is also characterized by chronic inflammation of the gastrointestinal tract. Basically, very early onset inflammatory bowel disease should be considered as an immunodeficiency with monogenic origin where both gastrointestinal manifestations and symptoms of immunodeficiencies may develop in variable combinations. However, in the future, the evaluation of genetic alterations in the background of the disease will probably be performed by next-generation sequencing technology; one should also consider that the sequence of the DNA stands in continuous interaction with a wide variety of environmental effects, among which nutrition should be emphasized by all means. Read More

View Article
December 2018

Differences in peripheral and tissue immune cell populations following hematopoietic stem cell transplantation in Crohn's disease patients.

J Crohns Colitis 2018 Dec 6. Epub 2018 Dec 6.

Department of Gastroenterology, IDIBAPS, Hospital Clínic, Barcelona, Spain.

Background And Aims: Recent studies show the efficacy of autologous hematopoietic stem cell transplantation (HSCT) in severely refractory Crohn's disease (CD) patients. HSCT is thought to eliminate auto-reactive cells; however, no specific studies of immune reconstitution in CD patients are available.

Methods: We followed a group of CD patients (n=18) receiving autologous HSCT, with 50% of them achieving endoscopic drug-free remission. Read More

View Article
December 2018
2 Reads
6.234 Impact Factor

Role of epithelial-to-mesenchymal transition in inflammatory bowel disease.

J Crohns Colitis 2018 Dec 6. Epub 2018 Dec 6.

IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy.

Intestinal fibrosis is an inevitable complication in patients with inflammatory bowel disease (IBD), occurring in its two major clinical manifestations: ulcerative colitis and Crohn's disease. Fibrosis represents the final outcome of the host reaction to persistent inflammation which triggers a prolonged wound healing response resulting in the excessive deposition of extracellular matrix, eventually leading to intestinal dysfunction. The process of epithelial-to-mesenchymal transition (EMT) represents an embryonic program relaunched during wound healing, fibrosis and cancer. Read More

View Article
December 2018
2 Reads

Application of a linear stapler to the laparoscopic treatment of gastrocolic fistula in patients with Crohn's disease.

Tech Coloproctol 2018 Dec 5. Epub 2018 Dec 5.

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

View Article
December 2018

Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study.

J Gastroenterol 2018 Dec 5. Epub 2018 Dec 5.

Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7 Kita-ku, Sapporo, 060-8638, Japan.

Background: Transabdominal ultrasonography (US) has been reported to be a useful tool for evaluating ulcerative colitis (UC) although with less well-established data than for Crohn's disease. This prospective multicenter study aimed to establish the usefulness of US compared with colonoscopy (CS) for assessing disease extent and activity of UC.

Methods: Altogether, 173 patients with UC were prospectively enrolled, among whom 156 were eligible for this study. Read More

View Article
December 2018

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.

Psoriasis (Auckl) 2018 13;8:83-92. Epub 2018 Nov 13.

Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal,

Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients' quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal antibody which targets IL-23p19 without binding IL-12. Read More

View Article
November 2018
1 Read

Microbiota profile in new-onset pediatric Crohn's disease: data from a non-Western population.

Gut Pathog 2018 29;10:49. Epub 2018 Nov 29.

7Physics Department, Boston University, Boston, USA.

Background: The role of microbiota in Crohn's disease (CD) is increasingly recognized. However, most of the reports are from Western populations. Considering the possible variation from other populations, the aim of this study was to describe the microbiota profile in children with CD in Saudi Arabia, a non-Western developing country population. Read More

View Article
November 2018
1 Read

Non-coding Class Switch Recombination-Related Transcription in Human Normal and Pathological Immune Responses.

Front Immunol 2018 21;9:2679. Epub 2018 Nov 21.

Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico.

Antibody class switch recombination (CSR) to IgG, IgA, or IgE is a hallmark of adaptive immunity, allowing antibody function diversification beyond IgM. CSR involves a deletion of the IgM/IgD constant region genes placing a new acceptor Constant gene, downstream of the VDJ exon. CSR depends on non-coding (CSRnc) transcription of donor I and acceptor I exons, located 5' upstream of each C coding gene. Read More

View Article
November 2018
1 Read

Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study.

Clin Epidemiol 2018 8;10:1613-1626. Epub 2018 Nov 8.

Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Background And Aims: Canada's large geographic area and low population density pose challenges in access to specialized health care for remote and rural residents. We compared health services use, surgical rate, and specialist gastroenterologist care in rural and urban inflammatory bowel disease (IBD) patients in Canada.

Methods: We used validated algorithms that were applied to population-based health administrative data to identify all people living with the following three Canadian provinces: Alberta, Manitoba, and Ontario (ON). Read More

View Article
November 2018